**This commentary refers to 'Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection', by S. Sala *et al*., doi:10.1093/eurheartj/ehaa286.**

Since the first cases reported in Wuhan, China, coronavirus disease 2019 (COVID-19) has spread swiftly around the world, and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The development of myocardial injury is associated with significantly worse clinical course and increased mortality. However, currently it is unclear whether cardiac injury observed in COVID-19 patients results directly from viral infection of the myocardium, i.e. SARS-CoV-2 viral myocarditis, or indirectly from the complications of COVID-19.

Several cases of acute myocarditis or, more appropriately, myocardial inflammation, associated with COVID-19 have been reported.[@ehaa392-B1]^,^[@ehaa392-B2] However, there are scant myocardial pathological data from COVID-19 patients. The only post-mortem pathological study in a COVID-19 patient thus far was on a 50-year-old male with COVID-19 who died from cardiac arrest, in China; the results showed significant lung damage, but no substantial damage in the myocardium was found except for a few interstitial mononuclear inflammatory infiltrates.[@ehaa392-B3]

In this issue, Sala *et al*. report the first direct evidence of myocardial inflammation by endomyocardial biopsy (EMB) in a COVID-19 patient.[@ehaa392-B2] EMB revealed diffuse T-lymphocytic inflammatory infiltrates with significant interstitial oedema and limited focal necrosis. However, no SARS-CoV-2 genome was detected within the myocardium.[@ehaa392-B2] On cardiac magnetic resonance (CMR), the patient had evidence of myocardial oedema and left ventricular systolic dysfunction with basal--mid left ventricular hypokinesis and preserved apical motion, a pattern indicative of reverse Takotsubo cardiomyopathy.[@ehaa392-B2]

Takotsubo cardiomyopathy is known to have regional myocardial oedema on CMR,[@ehaa392-B4] and injury to myocytes and infiltration of lymphocytes and macrophages in the autopsied specimens.[@ehaa392-B5] Given the lack of evident myocardial SARS-CoV-2 viral genome and shared CMR feathers with Takotsubo cardiomyopathy, the cardiac manifestation in this reported COVID-19 patient could be that of reverse Takotsubo cardiomyopathy in the setting of COVID-19 stress.[@ehaa392-B4]

Nevertheless, EBM is limited by sampling error and usually only a portion of patients infected with a virus causing myocarditis develop viral myocarditis; therefore, it is possible that with more autopsy evidence of SARS-CoV-2, viral myocarditis will emerge.
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